Boston Partners’s Charles River Laboratories CRL Stock Holding History

Boston Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-37,394	Closed	-$2.96M	–	710
2015 Q1	$2.96M	Sell	37,394 -8,615	-19%	-$636K	﹤0.01%	578
2014 Q4	$2.93M	Sell	46,009 -2,152	-4%	-$135K	﹤0.01%	602
2014 Q3	$2.88M	Hold	48,161	–	–	﹤0.01%	592
2014 Q2	$2.58M	Buy	48,161 +543	+1%	+$29.8K	﹤0.01%	606
2014 Q1	$2.87M	Sell	47,618 -4,667	-9%	-$272K	0.01%	591
2013 Q4	$2.77M	Hold	52,285	–	–	0.01%	587
2013 Q3	$2.42M	Sell	52,285 -30	-0.1%	-$1.38K	0.01%	579
2013 Q2	$2.15M	Buy	+52,315	New	+$2.24M	0.01%	590

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Boston Partners's CRL Position: Q2 2015 in Review

Boston Partners sold out of Charles River Laboratories (CRL) in Q2 2015, closing a stake of 37,394 shares — an estimated $2.96M sold.

Boston Partners first reported a position in CRL in Q2 2013 and held it in 8 quarters. The position peaked at $2.96M in Q1 2015. 261 funds tracked by Wall St. Rank hold CRL as of Q2 2015.

Boston Partners reported no remaining Charles River Laboratories position as of Q2 2015 after selling out during the quarter.
Boston Partners sold 37,394 Charles River Laboratories shares in Q2 2015, an estimated $2.96M.
Boston Partners first reported a position in Charles River Laboratories in Q2 2013 and held it in 8 quarters.
Boston Partners's Charles River Laboratories position peaked at $2.96M in Q1 2015.
261 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2015.

Based on Boston Partners's 13F filing for Q2 2015, filed 10 Aug 2015.